REGINfo: Sanofi-Aventis - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$Sanofi-Aventis: Click to view the issuer\'s details$

Last update : 29/03/2019 >View issuer details

2020.11.23 | 22:08 | Share Buybacks / Share redemption disclosures

puce Sanofi: Disclosure of trading in own shares - HTML (w)

2020.11.23 | 22:08 | Share Buybacks / Share redemption disclosures

puce Sanofi : Déclaration des transactions sur actions propres - HTML (w)

2020.11.23 | 10:00 | Permanent Information Releases / General Company News

puce European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older - HTML (w)

2020.11.23 | 10:00 | Permanent Information Releases / General Company News

puce La Commission européenne approuve MenQuadfi®, la toute dernière innovation en matière de vaccin méningococcique (MenACWY), indiqué à partir de l’âge de 12 mois - HTML (w)

2020.11.18 | 19:12 | Permanent Information Releases / General Company News

puce European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older - HTML (w)

2020.11.18 | 19:12 | Permanent Information Releases / General Company News

puce La Commission européenne approuve Supemtek® (vaccin antigrippe recombinant quadrivalent) pour la prévention de la grippe chez l’adulte à partir de 18 ans - HTML (w)

2020.11.18 | 07:15 | Permanent Information Releases / General Company News

puce Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia - HTML (w)

2020.11.18 | 07:15 | Permanent Information Releases / General Company News

puce La FDA accorde une procédure accélérée au rilzabrutinib pour le traitement de la thrombocytopénie immune - HTML (w)

2020.11.18 | 07:00 | Permanent Information Releases / General Company News

puce FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease - HTML (w)

2020.11.18 | 07:00 | Permanent Information Releases / General Company News

puce La FDA accorde un examen prioritaire à l’avalglucosidase alpha, nouveau traitement potentiel de la maladie de Pompe - HTML (w)

2020.11.14 | 01:00 | Permanent Information Releases / General Company News

puce FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease - HTML (w)

2020.11.14 | 01:00 | Permanent Information Releases / General Company News

puce La FDA publie une lettre de réponse complète au sujet du sutimlimab, un médicament expérimental pour le traitement de l’hémolyse chez l’adulte atteint de la maladie des agglutinines froides - HTML (w)

2020.11.02 | 07:15 | Permanent Information Releases / General Company News

puce Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products - HTML (w)

2020.11.02 | 07:15 | Permanent Information Releases / General Company News

puce Sanofi propose d’acquérir Kiadis, une entreprise spécialisée dans les produits d’immunothérapie à base de cellules au stade clinique - HTML (w)

2020.10.29 | 14:50 | Permanent Information Releases / General Company News

puce European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab) - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 2994